Chemotherapy Research Today is a free monthly online journal that collates and summarizes the latest research about Chemotherapy, including details on cancer treatment, side effects, drugs.

Volume 5 (2008), Issue 12 (December)

1. Computerized model of cost-utility analysis for treatment of age-related macular degeneration.
   Ophthalmology, 115(12): 2192-8. [Abstract] [Full-text]
2. Reuse of carboplatin and paclitaxel in patients with relapsed endometrial cancer--the British Columbia Cancer Agency experience.
   Gynecol Oncol, 111(3): 474-7. [Abstract] [Full-text]
3. XRCC1 Arginine194Tryptophan and GGH-401Cytosine/Thymine polymorphisms are associated with response to platinum-based neoadjuvant chemotherapy in cervical cancer.
   Gynecol Oncol, 111(3): 509-15. [Abstract] [Full-text]
4. Neoadjuvant chemotherapy and conservative surgery for stage IB1 cervical cancer.
   Gynecol Oncol, 111(3): 438-43. [Abstract] [Full-text]
5. Phase II evaluation of topotecan and navelbine in patients with recurrent ovarian, fallopian tube or primary peritoneal cancer.
   Gynecol Oncol, 111(3): 467-73. [Abstract] [Full-text]
6. Combination gemcitabine, platinum, and bevacizumab for the treatment of recurrent ovarian cancer.
   Gynecol Oncol, 111(3): 461-6. [Abstract] [Full-text]
7. Neoadjuvant cisplatin and etoposide followed by radical hysterectomy for stage 1B-2B cervical cancer.
   Gynecol Oncol, 111(3): 444-8. [Abstract] [Full-text]
8. Embryonal rhabdomyosarcoma of the uterine cervix in a 41-year-old woman treated with radical hysterectomy and adjuvant chemotherapy.
   Gynecol Oncol, 111(3): 561-3. [Abstract] [Full-text]
9. The use of bevacizumab in refractory ovarian granulosa-cell carcinoma with symptomatic relief of ascites: a case report.
   Gynecol Oncol, 111(3): 527-9. [Abstract] [Full-text]
10. A phase I pharmacokinetic study of hypoxic abdominal stop-flow perfusion with gemcitabine in patients with advanced pancreatic cancer and refractory malignant ascites.
    Cancer Chemother Pharmacol, 63(2): 331-41. [Abstract] [Full-text]
11. Reversible posterior leukoencephalopathy syndrome following intravenous paclitaxel and intraperitoneal cisplatin chemotherapy for fallopian tube cancer.
    Gynecol Oncol, 111(3): 537-9. [Abstract] [Full-text]
12. Luteinized thecoma associated with sclerosing peritonitis--conservative surgical approach followed by corticosteroid and GnRH agonist treatment--a case report.
    Gynecol Oncol, 111(3): 540-3. [Abstract] [Full-text]
13. Phase I dose escalation study of docetaxel with a fixed dose of S-1 in combination chemotherapy for advanced gastric cancer.
    Cancer Chemother Pharmacol, 63(2): 253-60. [Abstract] [Full-text]
14. Phase I/II trial of combination therapy with S-1 and weekly paclitaxel in patients with unresectable or recurrent gastric cancer.
    Cancer Chemother Pharmacol, 63(2): 267-73. [Abstract] [Full-text]
15. Use of cholesterol-rich nanoparticles that bind to lipoprotein receptors as a vehicle to paclitaxel in the treatment of breast cancer: pharmacokinetics, tumor uptake and a pilot clinical study.
    Cancer Chemother Pharmacol, 63(2): 281-7. [Abstract] [Full-text]
16. Phase I dose-escalating study of 24-h continuous infusion of 5-fluorouracil in combination with weekly docetaxel and cisplatin in patients with advanced gastric cancer.
    Cancer Chemother Pharmacol, 63(2): 213-8. [Abstract] [Full-text]
17. Fibrinolytic therapy in pulmonary embolism: an evidence-based treatment algorithm.
    Am J Emerg Med, 27(1): 84-95. [Abstract] [Full-text]
18. An observational, prospective study comparing tibial and humeral intraosseous access using the EZ-IO.
    Am J Emerg Med, 27(1): 8-15. [Abstract] [Full-text]
19. Anti-infective photodynamic biomaterials for the prevention of intraocular lens-associated infectious endophthalmitis.
    Biomaterials, 30(4): 597-602. [Abstract] [Full-text]
20. Sequential delivery of dexamethasone and VEGF to control local tissue response for carbon nanotube fluorescence based micro-capillary implantable sensors.
    Biomaterials, 30(4): 622-31. [Abstract] [Full-text]
21. Results of a phase I/II British Society of Bone Marrow Transplantation study on PCR-based pre-emptive therapy with valganciclovir or ganciclovir for active CMV infection following alemtuzumab-based reduced intensity allogeneic stem cell transplantation.
    Leuk Res, 33(2): 244-9. [Abstract] [Full-text]
22. Calorimetric study as a potential test for choosing treatment of B-cell chronic lymphocytic leukemia.
    Leuk Res, 33(2): 308-14. [Abstract] [Full-text]
23. Acoustically active perfluorocarbon nanoemulsions as drug delivery carriers for camptothecin: drug release and cytotoxicity against cancer cells.
    Ultrasonics, 49(1): 39-46. [Abstract] [Full-text]
24. The therapeutic effect of OK-432 (picibanil) sclerotherapy for benign neck cysts.
    Laryngoscope, 118(12): 2177-81. [Abstract] [Full-text]
25. Hepatic siRNA delivery using recombinant human apolipoprotein A-I in mice.
    Biochem Biophys Res Commun, 378(2): 192-6. [Abstract] [Full-text]
26. Modulation of insulin resistance in ovariectomized rats by endurance exercise training and estrogen replacement.
    Metabolism, 58(1): 38-47. [Abstract] [Full-text]
27. Influence of modified transdermal hormone replacement therapy on the concentrations of hormones, growth factors, and bone mineral density in women with osteopenia.
    Metabolism, 58(1): 1-7. [Abstract] [Full-text]
28. Pediatric fatality secondary to EDTA chelation.
    Clin Toxicol (Phila), 46(10): 1083-4. [Abstract] [Full-text]
29. Rituximab combined with chemotherapy and interferon in follicular lymphoma patients: results of the GELA-GOELAMS FL2000 study.
    Blood, 112(13): 4824-31. [Abstract] [Full-text]
30. Patterns of abuse among unintentional pharmaceutical overdose fatalities.
    JAMA, 300(22): 2613-20. [Abstract] [Full-text]
31. Diagnostic testing or empirical therapy for patients hospitalized with suspected influenza: what to do?
    Clin Infect Dis, 48: S14-9. [Abstract] [Full-text]
32. Virological suppression achieved with suboptimal adherence levels among South African children receiving boosted protease inhibitor-based antiretroviral therapy.
    Clin Infect Dis, 48(1): e3-5. [Abstract] [Full-text]
33. Reducing uncertainties about the effects of chemoradiotherapy for cervical cancer: a systematic review and meta-analysis of individual patient data from 18 randomized trials.
    J Clin Oncol, 26(35): 5802-12. [Abstract] [Full-text]
34. Phase II study of carboplatin and pemetrexed for the treatment of platinum-sensitive recurrent ovarian cancer.
    J Clin Oncol, 26(35): 5761-6. [Abstract] [Full-text]
35. Phase III trial comparing concurrent biochemotherapy with cisplatin, vinblastine, dacarbazine, interleukin-2, and interferon alfa-2b with cisplatin, vinblastine, and dacarbazine alone in patients with metastatic malignant melanoma (E3695): a trial coordinated by the Eastern Cooperative Oncology Group.
    J Clin Oncol, 26(35): 5748-54. [Abstract] [Full-text]
36. Five-year data and prognostic factor analysis of oxaliplatin and irinotecan combinations for advanced colorectal cancer: N9741.
    J Clin Oncol, 26(35): 5721-7. [Abstract] [Full-text]
37. Phase III study of cisplatin, etoposide, and concurrent chest radiation with or without consolidation docetaxel in patients with inoperable stage III non-small-cell lung cancer: the Hoosier Oncology Group and U.S. Oncology.
    J Clin Oncol, 26(35): 5755-60. [Abstract] [Full-text]
38. Influence of pre- and post-transplantation responses on outcome of patients with multiple myeloma: sequential improvement of response and achievement of complete response are associated with longer survival.
    J Clin Oncol, 26(35): 5775-82. [Abstract] [Full-text]
39. Impact of disease risk on efficacy of matched related bone marrow transplantation for pediatric acute myeloid leukemia: the Children's Oncology Group.
    J Clin Oncol, 26(35): 5797-801. [Abstract] [Full-text]
40. Indoleamine 2,3-dioxygenase is highly expressed in human adult T-cell leukemia/lymphoma and chemotherapy changes tryptophan catabolism in serum and reduced activity.
    Leuk Res, 33(1): 39-45. [Abstract] [Full-text]
41. In vitro cellular drug sensitivity at diagnosis is correlated to minimal residual disease at end of induction therapy in childhood acute lymphoblastic leukemia.
    Leuk Res, 33(1): 46-53. [Abstract] [Full-text]
42. Developments in macromolecular drug delivery.
    Methods Mol Biol, 480: 1-10. [Abstract] [Full-text]
43. Preparation of macromolecule-containing dry powders for pulmonary delivery.
    Methods Mol Biol, 480: 165-74. [Abstract] [Full-text]
44. Macromolecular delivery across the blood-brain barrier.
    Methods Mol Biol, 480: 175-85. [Abstract] [Full-text]
45. Randomised phase II study of ASA404 combined with carboplatin and paclitaxel in previously untreated advanced non-small cell lung cancer.
    Br J Cancer, 99(12): 2006-12. [Abstract] [Full-text]
46. p53 Small-molecule inhibitor enhances temozolomide cytotoxic activity against intracranial glioblastoma xenografts.
    Cancer Res, 68(24): 10034-9. [Abstract] [Full-text]
47. Clinical study of sclerotherapy of maxillofacial venous malformation using absolute ethanol and pingyangmycin.
    J Oral Maxillofac Surg, 67(1): 98-104. [Abstract] [Full-text]
48. Defining the molecular action of HDAC inhibitors and synergism with androgen deprivation in ERG-positive prostate cancer.
    Int J Cancer, 123(12): 2774-81. [Abstract] [Full-text]
49. Photochemical sealing improves outcome following peripheral neurorrhaphy.
    J Surg Res, 151(1): 33-9. [Abstract] [Full-text]
50. Influence of repeated cycles of structured therapy interruption on the rate of recovery of CD4+ T cells after highly active antiretroviral therapy resumption.
    J Antimicrob Chemother, 63(1): 184-8. [Abstract] [Full-text]
51. Effects of a pharmacist-to-dose computerized request on promptness of antimicrobial therapy.
    J Am Med Inform Assoc, 16(1): 47-53. [Abstract] [Full-text]
52. Impact of non-interruptive medication laboratory monitoring alerts in ambulatory care.
    J Am Med Inform Assoc, 16(1): 66-71. [Abstract] [Full-text]
53. Synergistic effects of acyclic retinoid and gemcitabine on growth inhibition in pancreatic cancer cells.
    Cancer Lett, 273(2): 250-6. [Abstract] [Full-text]
54. Treatment results in patients with retinoblastoma and invasion to the cut end of the optic nerve.
    Pediatr Blood Cancer, 52(2): 218-22. [Abstract] [Full-text]
55. Non-Hodgkin lymphoma (NHL) in children with Nijmegen Breakage syndrome (NBS).
    Pediatr Blood Cancer, 52(2): 186-90. [Abstract] [Full-text]
56. A study of rituximab and ifosfamide, carboplatin, and etoposide chemotherapy in children with recurrent/refractory B-cell (CD20+) non-Hodgkin lymphoma and mature B-cell acute lymphoblastic leukemia: a report from the Children's Oncology Group.
    Pediatr Blood Cancer, 52(2): 177-81. [Abstract] [Full-text]
57. Controlled release metformin hydrochloride microspheres of ethyl cellulose prepared by different methods and study on the polymer affected parameters.
    J Microencapsul, 26(1): 46-53. [Abstract] [Full-text]
58. Preparation and characterization of novel semi-interpenetrating polymer network hydrogel microspheres of chitosan and hydroxypropyl cellulose for controlled release of chlorothiazide.
    J Microencapsul, 26(1): 27-36. [Abstract] [Full-text]
59. Effect of drying processes and curing time of chitosan-lysine semi-IPN beads on chlorpheniramine maleate delivery.
    J Microencapsul, 26(1): 54-62. [Abstract] [Full-text]
60. Poly (epsilon-caprolactone) microparticles containing Levobunolol HCl prepared by a multiple emulsion (W/O/W) solvent evaporation technique: effects of some formulation parameters on microparticle characteristics.
    J Microencapsul, 26(1): 63-74. [Abstract] [Full-text]
61. Gel core liposomes: an advanced carrier for improved vaccine delivery.
    J Microencapsul, 26(1): 75-82. [Abstract] [Full-text]
62. Use of pharmacotherapy while attempting cessation among Italian smokers.
    Eur J Cancer Prev, 18(1): 90-2. [Abstract] [Full-text]
63. Phytochemicals as potential chemopreventive and chemotherapeutic agents in hepatocarcinogenesis.
    Eur J Cancer Prev, 18(1): 13-25. [Abstract] [Full-text]
64. Oil-filled polymer microcapsules for ultrasound-mediated delivery of lipophilic drugs.
    J Control Release, 133(2): 109-18. [Abstract] [Full-text]
65. A new double emulsion solvent diffusion technique for encapsulating hydrophilic molecules in PLGA nanoparticles.
    J Control Release, 133(2): 90-5. [Abstract] [Full-text]
66. Efficient tumor targeting of hydroxycamptothecin loaded PEGylated niosomes modified with transferrin.
    J Control Release, 133(2): 96-102. [Abstract] [Full-text]
67. Use of selective decontamination of the digestive tract in United Kingdom intensive care units.
    Anaesthesia, 64(1): 46-9. [Abstract] [Full-text]
68. Health-related quality of life and IGF-1 in GH-deficient adult patients on GH replacement therapy: analysis of the German KIMS data and the Study of Health in Pomerania.
    Eur J Endocrinol, 160(1): 17-24. [Abstract] [Full-text]
69. Thrombolysis during resuscitation for out-of-hospital cardiac arrest.
    N Engl J Med, 359(25): 2651-62. [Abstract] [Full-text]
70. Carboplatin and pegylated liposomal doxorubicin for advanced ovarian cancer: preliminary activity results of the MITO-2 phase III trial.
    Oncology, 76(1): 49-54. [Abstract] [Full-text]
71. Assessment of chemical coverage of kinome space and its implications for kinase drug discovery.
    J Med Chem, 51(24): 7898-914. [Abstract] [Full-text]
72. Analytical characterization of chitosan nanoparticles for peptide drug delivery applications.
    Anal Bioanal Chem, 393(1): 207-15. [Abstract] [Full-text]
73. Phase III trial of androgen ablation with or without three cycles of systemic chemotherapy for advanced prostate cancer.
    J Clin Oncol, 26(36): 5936-42. [Abstract] [Full-text]
74. Efficacy of oxaliplatin plus capecitabine or infusional fluorouracil/leucovorin in patients with metastatic colorectal cancer: a pooled analysis of randomized trials.
    J Clin Oncol, 26(36): 5910-7. [Abstract] [Full-text]
75. The new Food and Drug Administration drug package insert: implications for patient safety and clinical care.
    Anesth Analg, 108(1): 211-8. [Abstract] [Full-text]
76. Sequential continuous infusion of fludarabine and cytarabine associated with liposomal daunorubicin (DaunoXome) (FLAD) in primary refractory or relapsed adult acute myeloid leukemia patients.
    Ann Hematol, 88(2): 151-8. [Abstract] [Full-text]
77. Systemic high-dose methotrexate plus ifosfamide is highly effective for central nervous system (CNS) involvement of lymphoma.
    Ann Hematol, 88(2): 133-9. [Abstract] [Full-text]
78. Design and optimization of a new self-nanoemulsifying drug delivery system.
    J Colloid Interface Sci, 330(2): 443-8. [Abstract] [Full-text]
79. Development of Fe3O4-poly(L-lactide) magnetic microparticles in supercritical CO2.
    J Colloid Interface Sci, 330(2): 317-22. [Abstract] [Full-text]
80. Sustained delivery of timolol maleate from poly(lactic-co-glycolic acid)/poly(lactic acid) microspheres for over 3 months.
    J Microencapsul, 26(1): 18-26. [Abstract] [Full-text]
81. Particle size design of PLGA microspheres for potential pulmonary drug delivery using response surface methodology.
    J Microencapsul, 26(1): 1-8. [Abstract] [Full-text]
82. Concurrent carboplatin/paclitaxel and intravaginal radiation in surgical stage I-II serous endometrial cancer.
    Gynecol Oncol, 112(1): 142-5. [Abstract] [Full-text]
83. A phase I/II study of extended field radiation therapy with concomitant paclitaxel and cisplatin chemotherapy in patients with cervical carcinoma metastatic to the para-aortic lymph nodes: a Gynecologic Oncology Group study.
    Gynecol Oncol, 112(1): 78-84. [Abstract] [Full-text]
84. A feasibility study of topotecan with standard-dose cisplatin and concurrent primary radiation therapy in locally advanced cervical cancer.
    Gynecol Oncol, 112(1): 85-9. [Abstract] [Full-text]
85. Phase II trial of carboplatin and distearoylphosphatidylcholine pegylated liposomal doxorubicin (Lipo-Dox) in recurrent platinum-sensitive ovarian cancer following front-line therapy with paclitaxel and platinum.
    Gynecol Oncol, 112(1): 35-9. [Abstract] [Full-text]
86. Phase I trial of the treatment of high-risk endometrial cancer with concurrent weekly paclitaxel and cisplatin and whole abdominal radiation therapy: a Gynecologic Oncology Group study.
    Gynecol Oncol, 112(1): 134-41. [Abstract] [Full-text]
87. Stage IV ovarian cancer: disease site-specific rationale for postoperative treatment.
    Gynecol Oncol, 112(1): 22-7. [Abstract] [Full-text]
88. TP53, BCL-2 and BAX analysis in 199 ovarian cancer patients treated with taxane-platinum regimens.
    Gynecol Oncol, 112(1): 179-84. [Abstract] [Full-text]
89. Evaluation of a peritoneal surface disease severity score in patients with colon cancer with peritoneal carcinomatosis.
    J Surg Oncol, 99(1): 9-15. [Abstract] [Full-text]
90. Anterior juxtascleral delivery of anecortave acetate in eyes with primary open-angle glaucoma: a pilot investigation.
    Am J Ophthalmol, 147(1): 45-50.e2. [Abstract] [Full-text]
91. Inhibition and dispersion of Pseudomonas aeruginosa biofilms by glycopeptide dendrimers targeting the fucose-specific lectin LecB.
    Chem Biol, 15(12): 1249-57. [Abstract] [Full-text]
92. Mechanical pleurodesis aided by peritoneal drainage: procedure for hepatic hydrothorax.
    Ann Thorac Surg, 87(1): 245-50. [Abstract] [Full-text]
93. N-acetylcysteine in cardiovascular-surgery-associated renal failure: a meta-analysis.
    Ann Thorac Surg, 87(1): 139-47. [Abstract] [Full-text]
94. Evaluation of patients with esophageal varices after endoscopic injection sclerotherapy using multiplanar reconstruction MDCT images.
    AJR Am J Roentgenol, 192(1): 122-30. [Abstract] [Full-text]
95. Bevacizumab plus irinotecan in the treatment patients with progressive recurrent malignant brain tumours.
    Acta Oncol, 48(1): 52-8. [Abstract] [Full-text]
96. Renal function after ifosfamide, carboplatin and etoposide (ICE) chemotherapy, nephrectomy and radiotherapy in children with Wilms tumour.
    Eur J Cancer, 45(1): 99-106. [Abstract] [Full-text]
97. An EORTC phase I study of Bortezomib in combination with oxaliplatin, leucovorin and 5-fluorouracil in patients with advanced colorectal cancer.
    Eur J Cancer, 45(1): 48-55. [Abstract] [Full-text]
98. Neuropsychological functioning in postmenopausal breast cancer patients treated with tamoxifen or exemestane after AC-chemotherapy: cross-sectional findings from the neuropsychological TEAM-side study.
    Acta Oncol, 48(1): 76-85. [Abstract] [Full-text]
99. Oxaliplatin and capecitabine-based chemoradiotherapy for gastric cancer--an extended phase I MARGIT and AIO trial.
    Int J Radiat Oncol Biol Phys, 73(1): 142-7. [Abstract] [Full-text]
100. Prospective study of alternating chemoradiotherapy consisting of extended-field dynamic conformational radiotherapy and systemic chemotherapy using 5-FU and nedaplatin for patients in high-risk group with cervical carcinoma.
     Int J Radiat Oncol Biol Phys, 73(1): 251-8. [Abstract] [Full-text]
101. A phase I trial of 5-fluorouracil with cisplatin and concurrent standard-dose radiotherapy in Japanese patients with stage II/III esophageal cancer.
     Jpn J Clin Oncol, 39(1): 37-42. [Abstract] [Full-text]
102. S-1 and gemcitabine as an outpatient-based regimen in patients with advanced or metastatic pancreatic cancer.
     Jpn J Clin Oncol, 39(1): 49-53. [Abstract] [Full-text]
103. Oral fluoropyrimidines (capecitabine or S-1) and cisplatin as first line treatment in elderly patients with advanced gastric cancer: a retrospective study.
     Jpn J Clin Oncol, 39(1): 43-8. [Abstract] [Full-text]
104. Phase II study of 5-fluorouracil and paclitaxel in patients with gemcitabine-refractory pancreatic cancer.
     Cancer Chemother Pharmacol, 63(3): 529-33. [Abstract] [Full-text]
105. Phase I/II trial with docetaxel and S-1 for patients with advanced or recurrent gastric cancer with consideration to age.
     Cancer Chemother Pharmacol, 63(3): 509-16. [Abstract] [Full-text]
106. Combination chemotherapy of biweekly irinotecan (CPT-11) plus tegafur/uracil (UFT) and leucovorin (LV) for patients with metastatic colorectal cancer: phase I/II study in Japanese patients.
     Cancer Chemother Pharmacol, 63(3): 501-7. [Abstract] [Full-text]
107. A Bayesian population PK-PD model for ispinesib/docetaxel combination-induced myelosuppression.
     Cancer Chemother Pharmacol, 63(3): 469-76. [Abstract] [Full-text]
108. Efficacy of combination chemotherapy with capecitabine plus cisplatin in patients with unresectable hepatocellular carcinoma.
     Cancer Chemother Pharmacol, 63(3): 459-67. [Abstract] [Full-text]
109. Phase II trial of biweekly paclitaxel plus infusional 5-fluorouracil and leucovorin in patients with advanced or recurrent inoperable gastric cancer.
     Cancer Chemother Pharmacol, 63(3): 427-32. [Abstract] [Full-text]
110. Phase I clinical and pharmacokinetic study of oxaliplatin, irinotecan and capecitabine.
     Cancer Chemother Pharmacol, 63(3): 441-50. [Abstract] [Full-text]
111. Phase 1 and pharmacokinetic study of weekly docosahexaenoic acid-paclitaxel, Taxoprexin, in resistant solid tumor malignancies.
     Cancer Chemother Pharmacol, 63(3): 451-8. [Abstract] [Full-text]
112. Combination therapy with docetaxel and low dose of cisplatin in elderly patients with advanced non-small cell lung cancer: multicenter phase II study.
     Cancer Chemother Pharmacol, 63(3): 403-9. [Abstract] [Full-text]
113. Treatment outcomes of oxaliplatin, 5-FU, and leucovorin as salvage therapy for patients with advanced or metastatic gastric cancer: a retrospective analysis.
     Cancer Chemother Pharmacol, 63(3): 433-9. [Abstract] [Full-text]
114. Patients' ideas, concerns, and expectations (ICE) in general practice: impact on prescribing.
     Br J Gen Pract, 59(558): 29-36. [Abstract] [Full-text]
115. Molecular design of protein-based nanocapsules for stimulus-responsive characteristics.
     Bioorg Med Chem, 17(1): 85-93. [Abstract] [Full-text]
116. Oral cyclosporine A--the current picture of its liposomal and other delivery systems.
     Cell Mol Biol Lett, 14(1): 139-52. [Abstract] [Full-text]
117. Targeted delivery of activatable fluorescent pro-apoptotic peptide into live cells.
     Org Biomol Chem, 7(2): 221-4. [Abstract] [Full-text]
118. A model ternary heparin conjugate by direct covalent bond strategy applied to drug delivery system.
     Bioorg Med Chem Lett, 19(1): 149-52. [Abstract] [Full-text]
119. Treatment of resistant human colon cancer xenografts by a fluoxetine-doxorubicin combination enhances therapeutic responses comparable to an aggressive bevacizumab regimen.
     Cancer Lett, 274(1): 118-25. [Abstract] [Full-text]
120. Monitoring medication use in older adults.
     Am J Nurs, 109(1): 68-78; quiz 78-9. [Abstract] [Full-text]
121. Drug carrier systems based on collagen-alginate composite structures for improving the performance of GDNF-secreting HEK293 cells.
     Biomaterials, 30(6): 1214-21. [Abstract] [Full-text]
122. Simultaneous intracellular delivery of targeting antibodies and functional nanoparticles with engineered protein G system.
     Biomaterials, 30(6): 1197-204. [Abstract] [Full-text]
123. Protamine sulfate/poly(L-aspartic acid) polyionic complexes self-assembled via electrostatic attractions for combined delivery of drug and gene.
     Biomaterials, 30(6): 1246-53. [Abstract] [Full-text]
124. Design and in vivo evaluation of a patch system based on thiolated polymers.
     J Pharm Sci, 98(2): 620-7. [Abstract] [Full-text]
125. Compatibility of a protein topical gel with wound dressings.
     J Pharm Sci, 98(2): 595-605. [Abstract] [Full-text]
126. Identification of tight junction modulating lipids.
     J Pharm Sci, 98(2): 606-19. [Abstract] [Full-text]
127. Enhanced cytotoxicity of core modified chitosan based polymeric micelles for doxorubicin delivery.
     J Pharm Sci, 98(2): 704-12. [Abstract] [Full-text]
128. Development and in vitro evaluation of a mucoadhesive vaginal delivery system for nystatin.
     J Pharm Sci, 98(2): 555-64. [Abstract] [Full-text]
129. Insulin loaded PLGA microspheres: effect of zinc salts on encapsulation, release, and stability.
     J Pharm Sci, 98(2): 529-42. [Abstract] [Full-text]
130. Characterization and optimization of AMG 517 supersaturatable self-emulsifying drug delivery system (S-SEDDS) for improved oral absorption.
     J Pharm Sci, 98(2): 516-28. [Abstract] [Full-text]
131. Enhancement of drug solubility in supramolecular and colloidal systems.
     J Pharm Sci, 98(2): 484-94. [Abstract] [Full-text]
132. Porcine buccal mucosa as an in vitro model: relative contribution of epithelium and connective tissue as permeability barriers.
     J Pharm Sci, 98(2): 471-83. [Abstract] [Full-text]
133. Production of solid lipid submicron particles for protein delivery using a novel supercritical gas-assisted melting atomization process.
     J Pharm Sci, 98(2): 640-50. [Abstract] [Full-text]
134. Controlled release scaffolds for bone tissue engineering.
     J Pharm Sci, 98(2): 430-41. [Abstract] [Full-text]
135. The cost-effectiveness of hormone therapy in younger and older postmenopausal women.
     Am J Med, 122(1): 42-52.e2. [Abstract] [Full-text]
136. HIV/AIDS: the management of treatment-experienced HIV-infected patients: new drugs and drug combinations.
     Clin Infect Dis, 48(2): 214-21. [Abstract] [Full-text]
137. Solution-processable stiff dendrimers: synthesis, photophysics, film morphology, and electroluminescence.
     J Org Chem, 74(1): 383-95. [Abstract] [Full-text]

© 2004-2012 Chemotherapy Research Today. All Rights Reserved.